Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study-Reference-Cited by-同舟云学术

Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate: Results From a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study

Published:2014-11-25 Issue:12 Volume:66 Page:3255-3264
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Weinblatt Michael E.¹,Genovese Mark C.²,Ho Meilien³,Hollis Sally³,Rosiak-Jedrychowicz Krystyna⁴,Kavanaugh Arthur⁵,Millson David S.³,Leon Gustavo⁶,Wang Millie³,van der Heijde Désirée⁷

Affiliation:

1. Brigham and Women's Hospital; Boston Massachusetts

2. Stanford University; Palo Alto California

3. AstraZeneca R&D, Alderley Park; Macclesfield UK

4. Przychodnia Neuromedyka; Żyrardów Poland

5. University of California, San Diego; La Jolla California

6. Instituto de Ginecología y Reproducción-Cirugía Mínimamente Invasiva; Lima Peru

7. Leiden University Medical Center; Leiden The Netherlands

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy